The challenges of bringing autologous HSP-based vaccines to commercial reality

Author： Gordon N.F.   Clark B.L.  

Publisher： Elsevier

ISSN： 1046-2023

Source： Methods, Vol.32, Iss.1, 2004-01, pp. : 63-69

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Messenger RNA-based vaccines

By Pascolo Steve  

Expert Opinion on Biological Therapy, Vol. 4, Iss. 8, 2004-08 ,pp. : 1285-1294

Informa Healthcare

Access to resources Recommend Favorite

Peptide-based vaccines for cancer immunotherapy

By Brinkman Joeli A   Fausch Steven C   Weber Jeffrey S   Kast W Martin  

Expert Opinion on Biological Therapy, Vol. 4, Iss. 2, 2004-02 ,pp. : 181-198

Informa Healthcare

Access to resources Recommend Favorite

DNA vaccines coding for heat-shock proteins (HSPs): tools for the activation of HSP-specific regulatory T cells

By Quintana Francisco J   Cohen Irun R  

Expert Opinion on Biological Therapy, Vol. 5, Iss. 4, 2005-04 ,pp. : 545-554

Informa Healthcare

Access to resources Recommend Favorite

Development of cancer vaccines using autologous and recombinant high molecular weight stress proteins

By Wang X.-Y.   Manjili M.H.   Park J.   Chen X.   Repasky E.   Subjeck J.R.  

Methods, Vol. 32, Iss. 1, 2004-01 ,pp. : 13-20

Elsevier

Access to resources Recommend Favorite

Dendritic cell-based vaccines and therapies for cancer

By Tatsumi Tomohide   Storkus Walter J  

Expert Opinion on Biological Therapy, Vol. 2, Iss. 8, 2002-12 ,pp. : 919-928

Informa Healthcare

Access to resources Recommend Favorite